Yvan Torrente

List of Publications by Year
in descending order

120 papers	7,501 citations	87843 38 h-index	53190 85 g-index
126 all docs	126 docs citations	126 times ranked	8686 citing authors

#	Article	IF	Citations
1	Effective high-throughput isolation of enriched platelets and circulating pro-angiogenic cells to accelerate skin-wound healing. Cellular and Molecular Life Sciences, 2022, 79, 259.	2.4	3
2	Metformin rescues muscle function in BAG3 myofibrillar myopathy models. Autophagy, 2021, 17, 2494-2510.	4.3	22
3	Effect of myofibril architecture on the active contraction of dystrophic muscle. A mathematical model. Journal of the Mechanical Behavior of Biomedical Materials, 2021, 114, 104214.	1.5	2
4	Shotgun Proteomics of Isolated Urinary Extracellular Vesicles for Investigating Respiratory Impedance in Healthy Preschoolers. Molecules, 2021, 26, 1258.	1.7	2
5	Functionalized Scintillating Nanotubes for Simultaneous Radio- and Photodynamic Therapy of Cancer. ACS Applied Materials & Interfaces, 2021, 13, 12997-13008.	4.0	13
6	Defective dystrophic thymus determines degenerative changes in skeletal muscle. Nature Communications, 2021, 12, 2099.	5.8	13
7	Clinical Determinants of Disease Progression in Patients With Beta-Sarcoglycan Gene Mutations. Frontiers in Neurology, 2021, 12, 657949.	1.1	5
8	Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies. Frontiers in Immunology, 2021, 12, 666879.	2.2	7
9	Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle. Frontiers in Genetics, 2021, 12, 702547.	1.1	18
10	Treatment with ROS detoxifying gold quantum clusters alleviates the functional decline in a mouse model of Friedreich ataxia. Science Translational Medicine, 2021, 13, .	5.8	7
11	The Immune System in Duchenne Muscular Dystrophy Pathogenesis. Biomedicines, 2021, 9, 1447.	1.4	19
12	Flavonoids and Omega3 Prevent Muscle and Cardiac Damage in Duchenne Muscular Dystrophy Animal Model. Cells, 2021, 10, 2917.	1.8	2
13	Behavioral Variant of Frontotemporal Dementia and Homicide in a Historical Case. Journal of the American Academy of Psychiatry and the Law, 2021, 49, 219-227.	0.2	2
14	A mathematical model of healthy and dystrophic skeletal muscle biomechanics. Journal of the Mechanics and Physics of Solids, 2020, 134, 103747.	2.3	4
15	Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy. EMBO Molecular Medicine, 2020, 12, e11019.	3.3	18
16	Interstitial Cell Remodeling Promotes Aberrant Adipogenesis in Dystrophic Muscles. Cell Reports, 2020, 31, 107597.	2.9	64
17	MICAL2 is essential for myogenic lineage commitment. Cell Death and Disease, 2020, 11, 654.	2.7	17
18	PTX3 Predicts Myocardial Damage and Fibrosis in Duchenne Muscular Dystrophy. Frontiers in Physiology, 2020, 11, 403.	1.3	15

#	Article	IF	Citations
19	Role of Insulin-Like Growth Factor Receptor 2 across Muscle Homeostasis: Implications for Treating Muscular Dystrophy. Cells, 2020, 9, 441.	1.8	22
20	A Special Amino-Acid Formula Tailored to Boosting Cell Respiration Prevents Mitochondrial Dysfunction and Oxidative Stress Caused by Doxorubicin in Mouse Cardiomyocytes. Nutrients, 2020, 12, 282.	1.7	27
21	Generation of the Becker muscular dystrophy patient derived induced pluripotent stem cell line carrying the DMD splicing mutation c.1705-8 T>C.. Stem Cell Research, 2020, 45, 101819.	0.3	2
22	Topical treatment of radiation-induced dermatitis: current issues and potential solutions. Drugs in Context, 2020, 9, 1-13.	1.0	25
23	Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial. Frontiers in Neurology, 2019, 10, 755.	1.1	19
24	Establishment of a Duchenne muscular dystrophy patient-derived induced pluripotent stem cell line carrying a deletion of exons 51â€“53 of the dystrophin gene (CCMi003-A). Stem Cell Research, 2019, 40, 101544.	0.3	4
25	Myalgia, Obtundity and Fever in a Patient with a Prosthesis. European Journal of Case Reports in Internal Medicine, 2019, 6, 001021.	0.2	0
26	Fibrosis Rescue Improves Cardiac Function in Dystrophin-Deficient Mice and Duchenne Patientâ€“Specific Cardiomyocytes by Immunoproteasome Modulation. American Journal of Pathology, 2019, 189, 339-353.	1.9	27
27	Myalgia, Obtundity and Fever in a Patient with a Prosthesis. European Journal of Case Reports in Internal Medicine, 2019, , .	0.2	0
28	Demonstration of cellular imaging by using luminescent and anti-cytotoxic europium-doped hafnia nanocrystals. Nanoscale, 2018, 10, 7933-7940.	2.8	24
29	Selfâ€Assembled pHâ€Sensitive Fluoromagnetic Nanotubes as Archetype System for Multimodal Imaging of Brain Cancer. Advanced Functional Materials, 2018, 28, 1707582.	7.8	22
30	Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol. American Journal of Transplantation, 2018, 18, 590-603.	2.6	53
31	Supplementation with a selective amino acid formula ameliorates muscular dystrophy in mdx mice. Scientific Reports, 2018, 8, 14659.	1.6	22
32	Purkinje cell COX deficiency and mtDNA depletion in an animal model of spinocerebellar ataxia type 1. Journal of Neuroscience Research, 2018, 96, 1576-1585.	1.3	12
33	Stem Cell Therapy in Duchenne Muscular Dystrophy. Molecular and Translational Medicine, 2017, , 297-317.	0.4	0
34	Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I. Human Molecular Genetics, 2017, 26, 3682-3698.	1.4	20
35	P(NIPAAM-co-HEMA) thermoresponsive hydrogels: an alternative approach for muscle cell sheet engineering. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 187-196.	1.3	13
36	Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS ONE, 2016, 11, e0151445.	1.1	32

#	Article	IF	Citations
37	Bioimaging: Self-Assembled Dual Dye-Doped Nanosized Micelles for High-Contrast Up-Conversion Bioimaging (Adv. Funct. Mater. 46/2016). Advanced Functional Materials, 2016, 26, 8446-8446.	7.8	3
38	Impaired Angiogenic Potential of Human Placental Mesenchymal Stromal Cells in Intrauterine Growth Restriction. Stem Cells Translational Medicine, 2016, 5, 451-463.	1.6	22
39	Permanent excimer superstructures by supramolecular networking of metal quantum clusters. Science, 2016, 353, 571-575.	6.0	54
40	Exome sequencing identifies variants in two genes encoding the LIM-proteins NRAP and FHL1 in an Italian patient with BAG3 myofibrillar myopathy. Journal of Muscle Research and Cell Motility, 2016, 37, 101-115.	0.9	23
41	Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs. Molecular Therapy, 2016, 24, 1949-1964.	3.7	24
42	Duchenne muscular dystrophy caused by a frame-shift mutation in the acceptor splice site of intron 26. BMC Medical Genetics, 2016, 17, 55.	2.1	5
43	Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy. Molecular Therapy, 2016, 24, 1898-1912.	3.7	37
44	Longitudinal <scp>MRI</scp> quantification of muscle degeneration in Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2016, 3, 607-622.	1.7	50
45	Selfâ€Assembled Dual Dyeâ€Doped Nanosized Micelles for Highâ€Contrast Upâ€Conversion Bioimaging. Advanced Functional Materials, 2016, 26, 8447-8454.	7.8	58
46	Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle. Development (Cambridge), 2016, 143, 658-669.	1.2	22
47	Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle. Journal of Cell Science, 2016, 129, e1.2-e1.2.	1.2	0
48	Intraâ€arterial transplantation of <scp>HLA</scp> â€matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Molecular Medicine, 2015, 7, 1513-1528.	3.3	146
49	Stem Cell Salvage of Injured Peripheral Nerve. Cell Transplantation, 2015, 24, 213-222.	1.2	17
50	Improvement of Endurance of DMD Animal Model Using Natural Polyphenols. BioMed Research International, 2015, 2015, 1-17.	0.9	11
51	Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect. Current Gene Therapy, 2015, 15, 563-571.	0.9	2
52	Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. PLoS ONE, 2014, 9, e108205.	1.1	98
53	Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies. BioMed Research International, 2014, 2014, 1-16.	0.9	8
54	Advancements in stem cells treatment of skeletal muscle wasting. Frontiers in Physiology, 2014, 5, 48.	1.3	18

#	Article	IF	Citations
55	Polyglycolic Acidâ€“Polylactic Acid Scaffold Response to Different Progenitor Cell In Vitro Cultures: A Demonstrative and Comparative X-Ray Synchrotron Radiation Phase-Contrast Microtomography Study. Tissue Engineering - Part C: Methods, 2014, 20, 308-316.	1.1	32
56	6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes. PLoS ONE, 2014, 9, e83400.	1.1	65
57	Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. PLoS ONE, 2014, 9, e114787.	1.1	33
58	Stem Cells in Dystrophic Animal Models: From Preclinical to Clinical Studies. Pancreatic Islet Biology, 2014, , 3-30.	0.1	0
59	Perspectives of stem cell therapy in <scp>D</scp>uchenne muscular dystrophy. FEBS Journal, 2013, 280, 4251-4262.	2.2	30
60	The involvement of microRNAs in neurodegenerative diseases. Frontiers in Cellular Neuroscience, 2013, 7, 265.	1.8	209
61	Fullâ€length dysferlin expression driven by engineered human dystrophic blood derived <scp>CD</scp>133+ stem cells. FEBS Journal, 2013, 280, 6045-6060.	2.2	12
62	Correction: Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature, 2013, 494, 506-506.	13.7	6
63	CD133+ Cells for the Treatment of Degenerative Diseases: Update and Perspectives. Advances in Experimental Medicine and Biology, 2013, 777, 229-243.	0.8	4
64	24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2013, 8, e52512.	1.1	99
65	Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.5	81
66	The Role of Stem Cells in Muscular Dystrophies. Current Gene Therapy, 2012, 12, 192-205.	0.9	13
67	Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures. BMC Neurology, 2012, 12, 91.	0.8	52
68	Expression of CD20 reveals a new store-operated calcium entry modulator in skeletal muscle. International Journal of Biochemistry and Cell Biology, 2012, 44, 2095-2105.	1.2	9
69	Hmgb3 Is Regulated by MicroRNA-206 during Muscle Regeneration. PLoS ONE, 2012, 7, e43464.	1.1	35
70	Novel insight into stem cell trafficking in dystrophic muscles. International Journal of Nanomedicine, 2012, 7, 3059.	3.3	14
71	Transplantation of Genetically Corrected Human iPSC-Derived Progenitors in Mice with Limb-Girdle Muscular Dystrophy. Science Translational Medicine, 2012, 4, 140ra89.	5.8	269
72	Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model. Experimental Cell Research, 2012, 318, 1160-1174.	1.2	26

#	Article	IF	Citations
73	Duchenne Muscular Dystrophy: Isolation of CD133-Expressing Myogenic Progenitors from Blood and Muscle of DMD Patients. , 2012, , 277-285.		0
74	Stem Cellâ€“Mediated Transfer of a Human Artificial Chromosome Ameliorates Muscular Dystrophy. Science Translational Medicine, 2011, 3, 96ra78.	5.8	137
75	Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. Journal of Neurology, 2011, 258, 1610-1623.	1.8	134
76	AAV6-mediated Systemic shRNA Delivery Reverses Disease in a Mouse Model of Facioscapulohumeral Muscular Dystrophy. Molecular Therapy, 2011, 19, 2055-2064.	3.7	43
77	In VivoTracking of Stem Cell by Nanotechnologies: Future Prospects for Mouse to Human Translation. Tissue Engineering - Part B: Reviews, 2011, 17, 1-11.	2.5	21
78	Alpha sarcoglycan is required for FGF-dependent myogenic progenitor cell proliferation in vitro and in vivo. Development (Cambridge), 2011, 138, 4523-4533.	1.2	25
79	Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy. BMC Musculoskeletal Disorders, 2010, 11, 157.	0.8	29
80	Ex vivo expansion of human circulating myogenic progenitors on cluster-assembled nanostructured TiO2. Biomaterials, 2010, 31, 5385-5396.	5.7	21
81	Stem Cell Tracking by Nanotechnologies. International Journal of Molecular Sciences, 2010, 11, 1070-1081.	1.8	63
82	Stem Cell Therapies to Treat Muscular Dystrophy. BioDrugs, 2010, 24, 237-247.	2.2	40
83	CD133⁺cells isolated from various sources and their role in future clinical perspectives. Expert Opinion on Biological Therapy, 2010, 10, 1521-1528.	1.4	40
84	Combining Stem Cells and Exon Skipping Strategy to Treat Muscular Dystrophy. , 2010, , 249-256.		0
85	Identification of Different Genomic Deletions and One Duplication in the Dysferlin Gene Using Multiplex Ligation-Dependent Probe Amplification and Genomic Quantitative PCR. Genetic Testing and Molecular Biomarkers, 2009, 13, 439-442.	0.3	18
86	Immortalized Skin Fibroblasts Expressing Conditional MyoD as a Renewable and Reliable Source of Converted Human Muscle Cells to Assess Therapeutic Strategies for Muscular Dystrophies: Validation of an Exon-Skipping Approach to Restore Dystrophin in Duchenne Muscular Dystrophy Cells. Human Gene Therapy, 2009, 20, 784-790.	1.4	60
87	Organization of Extracellular Matrix Fibers Within Polyglycolic Acidâ€“Polylactic Acid Scaffolds Analyzed Using X-Ray Synchrotron-Radiation Phase-Contrast Micro Computed Tomography. Tissue Engineering - Part C: Methods, 2009, 15, 403-411.	1.1	31
88	In Vivo Myogenic Potential of Human CD133+ Muscle-derived Stem Cells: A Quantitative Study. Molecular Therapy, 2009, 17, 1771-1778.	3.7	131
89	Cell based therapy for duchenne muscular dystrophy. Journal of Cellular Physiology, 2009, 221, 526-534.	2.0	55
90	CD20-related signaling pathway is differently activated in normal and dystrophic circulating CD133+ stem cells. Cellular and Molecular Life Sciences, 2009, 66, 697-710.	2.4	10

#	Article	IF	Citations
91	Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. Neurobiology of Aging, 2009, 30, 752-758.	1.5	63
92	Expression of Parathyroid-Specific Genes in Vascular Endothelial Progenitors of Normal and Tumoral Parathyroid Glands. American Journal of Pathology, 2009, 175, 1200-1207.	1.9	7
93	Combining stem cells and exon skipping strategy to treat muscular dystrophy. Expert Opinion on Biological Therapy, 2008, 8, 1051-1061.	1.4	13
94	Correlation of Circulating CD133+ Progenitor Subclasses with a Mild Phenotype in Duchenne Muscular Dystrophy Patients. PLoS ONE, 2008, 3, e2218.	1.1	9
95	Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis. PLoS ONE, 2008, 3, e3223.	1.1	36
96	Effect of Human Skin-Derived Stem Cells on Vessel Architecture, Tumor Growth, and Tumor Invasion in Brain Tumor Animal Models. Cancer Research, 2007, 67, 3054-3063.	0.4	55
97	Restoration of Human Dystrophin Following Transplantation of Exon-Skipping-Engineered DMD Patient Stem Cells into Dystrophic Mice. Cell Stem Cell, 2007, 1, 646-657.	5.2	206
98	Stem and Progenitor Cells in Skeletal Muscle Development, Maintenance, and Therapy. Molecular Therapy, 2007, 15, 867-877.	3.7	522
99	Skin-derived stem cells transplanted into resorbable guides provide functional nerve regeneration after sciatic nerve resection. Glia, 2007, 55, 425-438.	2.5	80
100	T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. Journal of Pathology, 2007, 213, 229-238.	2.1	93
101	Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature Cell Biology, 2007, 9, 255-267.	4.6	899
102	High-resolution X-ray microtomography for three-dimensional visualization of human stem cell muscle homing. FEBS Letters, 2006, 580, 5759-5764.	1.3	37
103	VCAM-1 expression on dystrophic muscle vessels has a critical role in the recruitment of human blood-derived CD133+ stem cells after intra-arterial transplantation. Blood, 2006, 108, 2857-66.	0.6	25
104	Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature, 2006, 444, 574-579.	13.7	692
105	Galectin-1 Induces Skeletal Muscle Differentiation in Human Fetal Mesenchymal Stem Cells and Increases Muscle Regeneration. Stem Cells, 2006, 24, 1879-1891.	1.4	144
106	Correction: Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. Journal of Cell Biology, 2006, 175, 361-361.	2.3	0
107	Correction: Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration abilit. Journal of Cell Biology, 2006, 174, 605-605.	2.3	0
108	Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. Journal of Cell Biology, 2006, 174, 231-243.	2.3	187

#	Article	IF	Citations
109	Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. Journal of Experimental Medicine, 2006, 203, i21-i21.	4.2	0
110	Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. Journal of Neuroscience Research, 2004, 77, 475-486.	1.3	129
111	Human circulating AC133+ stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. Journal of Clinical Investigation, 2004, 114, 182-195.	3.9	315
112	Identification of a putative pathway for the muscle homing of stem cells in a muscular dystrophy model. Journal of Cell Biology, 2003, 162, 511-520.	2.3	59
113	Cell Therapy of Â-Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts. Science, 2003, 301, 487-492.	6.0	593
114	High-efficiency gene transfer into adult fish: A new tool to study fin regeneration. Genesis, 2002, 32, 27-31.	0.8	61
115	The role of interleukin-6 (IL-6) in the proliferation and differentiation of human neural stem cells. Neuroscience Research Communications, 2001, 29, 1-14.	0.2	0
116	?-enolase deficiency, a new metabolic myopathy of distal glycolysis. Annals of Neurology, 2001, 50, 202-207.	2.8	125
117	Intracellular Delivery of a Tat-eGFP Fusion Protein into Muscle Cells. Molecular Therapy, 2001, 3, 310-318.	3.7	139
118	Intra-aortic injection of myoblasts in mdx mice: Genetic and technetium-99m cell labeling and biodistribution. , 1997, 20, 757-759.		3
119	In vivo biolistic technique in control and mdx dystrophic mice. , 1996, 19, 912-914.		0
120	Stem Cell Therapy for Neuromuscular Diseases. , 0, , .		2